PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Prostacare Pty Ltd

USPTO PatentsView assignee record - 9 granted patents across 2 technology areas, recorded in grant years 2015–2022. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).

RSS updates for this company
Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Prostacare ranks #29,850 of 49,997 tracked US assignees by granted-patent volume, with 9 patents across 2 technology areas.

#29,850
of 49,997 US assignees by volume
29th percentile
by Innovation Score (28.8/100)
20.9
avg claims per patent
+100%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R29850 · Foreign Corporation #29,850 · 9 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

  • GRANTS-MICRO 9 grants
  • MID-PACK #29,850/49,997
  • PHOTO-FINISH Propagation…
  • CPC-NARROW A61B · 2 areas
  • INNOV-THIN 28.8/100
  • CLAIMS-DENSE 20.9 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-SURGE +100% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Propagation Research Associates LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Prostacare’s 28.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Prostacare

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Prostacare's Innovation Score is 28.8/100 (29th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Prostacare?

Each dot is one of Prostacare’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Prostacare’s own 20.9 claims/patent is ABOVE the 17.3 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Prostacare vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 8.98.999.1 0102030 Granted patents (volume) Avg claims / patent Propagation Research Associates LLC - 9, 25.22Propagation Resea…Prophet Productions, LLC - 9, 22.44Prophet Productio…Proserv Gilmore Valve LLC - 9, 15Proserv Gilmore V…Prosidyan, Inc. - 9, 17.33ProsidyanProstoria d.o.o. - 9, 1Prostoria d o oProterra Operating Company, Inc. - 9, 20.11Proterra OperatingProud Grill Company Limited - 9, 3Proud GrillPrysm Systems, Inc. - 9, 18.11Prysm SystemsProstacare Pty Ltd - 9, 20.89Prostacare Pty
Prostacare vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Prostacare's grants concentrate

Prostacare Pty Ltd is a focused PatentsView assignee: 2 CPC subclasses with 100% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). Peak complete grant year is 2020 (3 grants) versus a trough of 1 in 2015. By volume, Prostacare sits between Propagation Research Associates LLC and Prysm Systems, Inc..

Prostacare's three-year grant acceleration

Prostacare Pty Ltd shows 2 grants in 2022–2024 against only 4 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Prostacare's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Prostacare holds 9 patents at rank #29,830, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Prostacare

By rank, the assignees closest to #29,830 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in Prostacare's primary technology class.

Prostacare's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

29 29th percentile higher than 29% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.533.5 201520172018202020212022 2
USPTO utility patent grants by year · 2015–2022

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Prostacare Pty Ltd patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 1 11.1%
2017 1 11.1%
2018 1 11.1%
2020 3 33.3%
2021 1 11.1%
2022 2 22.2%

Which technologies does Prostacare Pty Ltd patent most?

Top 2 of 2 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Prostacare Pty Ltd's patent record in context - here's where to go next.

  • Prostacare Pty Ltd's lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 100% of its portfolio - see every assignee active in that class. Explore A61B
  • Ranked #29,850 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Prostacare Pty Ltd against Propagation Research Associates LLC, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 28.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.